Fundraising Fox
/People
Sign in

David Mott

Investor

Board director at Cydan II · Board director at Imara · Board director at Omthera Pharmaceuticals

Maryland

Midas 2019 · #86

Find your path to David

149 people in our graph can introduce you to David.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Rekha Hemrajani to introduce you to David

You →Rekha · together at Sagimet Biosciences →David

Ask Jamie Chen to introduce you to David

You →Jamie · together at Ardelyx →David

Ask Sam Okafor to introduce you to David

You →Sam · 2 people · together at Sagimet Biosciences →David

Sign up to find every way you can get introduced to David

  • Your email: the people you already email who know David
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with David
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

David Mott led New Enterprise Associates' healthcare investing as a general partner after serving as chief executive of biotech company MedImmune, which AstraZeneca acquired for $15.6 billion.

Board director at Cydan II

Intro paths

→

In turn, David can intro founders to Cydan II's investors below.

Cydan II's investors · 4

AlexandriaPasadena · since 2017Longitude CapitalMenlo Park · $10M – $30M checks · since 2017New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2017Pfizer Venture Investments$5M – $20M checks · since 2017

Board director at Imara

Intro paths

→

In turn, David can intro founders to Imara's investors below.

Imara's investors · 9

AlexandriaPasadena · since 2019Arix BioscienceLondon · since 2019Bay City CapitalSan Rafael · $5M – $10M checks · since 2019Lundbeckfonden VenturesKøbenhavn · since 2019New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2019OrbiMedNew York · $1M – $75M checks · since 2019Pfizer Venture Investments$5M – $20M checks · since 2019RA CapitalBoston · since 2019Rock Springs CapitalBaltimore · since 2019

Board director at Omthera Pharmaceuticals

Intro paths

→

In turn, David can intro founders to Omthera Pharmaceuticals's investors below.

Omthera Pharmaceuticals's investors · 2

New Enterprise Associates (NEA)Menlo Park · $200K – $40M checksSofinnova PartnersParis · $540K – $27M checks

Deals · 1

TesaroBoard seat

via New Enterprise Associates (NEA) · filed Apr 2016 · $50M raise

Attribution from SEC filings, press coverage, and firm rosters.

Frequently asked questions

Who is David Mott?
David Mott led New Enterprise Associates' healthcare investing as a general partner after serving as chief executive of biotech company MedImmune, which AstraZeneca acquired for $15.6 billion.
Where does David Mott work?
David Mott is Board director at Cydan II and Board director at Imara and Board director at Omthera Pharmaceuticals.
What boards does David Mott sit on?
David Mott holds tracked board seats at Tesaro.